Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.

@article{Chapman2013MechanismsOR,
  title={Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.},
  author={Paul B Chapman},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
  year={2013}
}
Treatment of V600E/K BRAF-mutated melanomas with RAF inhibitors (either vemurafenib or dabrafenib) results in rapid and dramatic responses in most patients-results that are associated with improved progression-free survival (PFS) and in the case of vemurafenib, overall survival (OS). However, resistance develops at a median time of approximately 6 months. Understanding the mechanisms of resistance is critical to develop strategies to prolong PFS and OS. Negative feedback mechanisms inherent in… CONTINUE READING